Article
The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid.
Thrombosis and haemostasis - 1 Jul 2008
Clappers Nick, van Oijen Martijn G H, Sundaresan Santosh, Brouwer Marc A, Te Morsche Rene H M, Keuper Wessel, Peters Wilbert H M, Drenth Joost P H, Verheugt Freek W A
Abstract excerpt
Aspirin prevents thrombotic events by inhibiting platelet cyclooxygenase-1 (COX-1), thus reducing thromboxane A2 formation and platelet aggregation. The C50T polymorphism of COX-1 is associated with an impaired inhibition of both thromboxane production and in-vitro platelet aggregation by aspirin. We studied whether this polymorphism is also associated with the risk of clinical thrombotic events in patients using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.